recombinant hepatitis B surface antigen + monophosphoryl lipid A + aluminium salts

This drug is a **combination vaccine formulation** containing three key components: - **recombinant hepatitis B surface antigen (HBsAg)**: a non-infectious antigen produced via recombinant DNA technology, usually in *Saccharomyces cerevisiae* or other yeast cells, which stimulates an immune response against hepatitis B virus[1][2][4][5][6][7]. - **monophosphoryl lipid A (MPL)**: a detoxified derivative of lipopolysaccharide (LPS) used as an adjuvant, known to enhance the immune response by activating Toll-like receptor 4 (TLR4) pathways, increasing both antibody and cellular responses. MPL is used in some advanced vaccine formulations for its strong immunostimulatory properties. - **aluminium salts** (typically aluminium hydroxide or aluminium hydroxyphosphate sulfate): an adjuvant that increases immunogenicity by promoting antigen uptake and activating the innate immune system[1][2][5][7]. This formulation is designed to achieve **effective active immunization against hepatitis B**, with enhanced immune activation due to MPL and aluminium salts. Such combination vaccines are investigated for improved immunogenicity, faster seroprotection, and better efficacy in populations with low response to standard hepatitis B vaccines. The primary indication is **prevention of hepatitis B virus infection**. Known analogues using similar combinations include certain investigational hepatitis B vaccines and chimeric particulate vaccines for infectious disease prevention[6][7].